These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18276097)

  • 21. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
    Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
    Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
    Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H; Dowzicky MJ
    Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU setting and different age groups: results from the tigecycline evaluation and Surveillance trial in North America.
    Low DE; Markovic MJ; Dowzicky MJ
    J Chemother; 2009 Feb; 21(1):16-23. PubMed ID: 19297267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL; Fung HB; Mehta D; Riska PF
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Waites KB; Duffy LB; Dowzicky MJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3479-84. PubMed ID: 17005838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.
    Bradford PA; Petersen PJ; Tuckman M; Jones CH
    Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activity of tigecycline against pathogen bacteria isolated in respiratory infectious disease in Europe. TEST study 2004-2007].
    Rio Y; Okamba P; Staal A; Didion J; Jurin F;
    Pathol Biol (Paris); 2009 Feb; 57(1):13-6. PubMed ID: 18829182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.
    Halstead DC; Abid J; Dowzicky MJ
    J Infect; 2007 Jul; 55(1):49-57. PubMed ID: 17250897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008).
    Tomic V; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2014 Nov; 13():52. PubMed ID: 25376749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy.
    Ramsamy Y; Muckart DJ; Han KS
    S Afr Med J; 2013 Mar; 103(6):371-6. PubMed ID: 23725954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.